A panel of experts who advise the U.S. Food and Drug Administration (FDA) agreed on June 9 that a late-stage study of a drug for Alzheimer’s disease showed that it was beneficial in slowing cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback